Skip to main content
PLOS One logoLink to PLOS One
. 2018 Oct 4;13(10):e0205567. doi: 10.1371/journal.pone.0205567

Correction: Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design

Hiroshi Wada, Atsushi Shimizu, Toshihiro Osada, Yuki Tanaka, Satoshi Fukaya, Eiji Sasaki
PMCID: PMC6171946  PMID: 30286206

There are typographical errors in the fourth and fifth sentences of the Abstract. “IFN-μ” should appear as “IFN-γ.” The correct sentences are: However, to confirm whether a multivalent vaccine can induce an individual epitope-specific CTL, the only viable screening strategies currently available are interferon-gamma (IFN-γ enzyme-linked immunospot (ELISPOT) assays using human peripheral blood mononuclear cells, or expensive human leukocyte antigen (HLA)-expressing mice. In this report, we evaluated the use of our developed murine-20S immunoproteasome (i20S) digestion assay and found that it could predict the results of IFN-γ ELISPOT assays.

There is a typographical error in the Abbreviations. “IFN-μΛ, interferon-gamma” should appear as “IFN-γ, interferon-gamma.”

Reference

  • 1.Wada H, Shimizu A, Osada T, Tanaka Y, Fukaya S, Sasaki E (2018) Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design. PLoS ONE 13(7): e0199249 10.1371/journal.pone.0199249 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES